Your browser doesn't support javascript.
loading
The D-HCM score, a new diagnostic tool for distinguishing hypertrophic cardiomyopathy from hypertensive cardiopathy.
Domain, G; Biscond, M; Dognin, N; Strube, C; Mondoly, P; Réant, P; Sarrazin, J F; Galinier, M; Champagne, J; Rollin, A; Carrié, D; Cochet, H; Lairez, O; Philippon, F; Ferrières, J; Maury, P; Steinberg, C.
Afiliación
  • Domain G; Institut universitaire de cardiologie et de pneumologie de Québec, Québec, Canada.
  • Biscond M; Hôpital Rangueil, University of Toulouse, Toulouse, France.
  • Dognin N; Collège des Sciences Humaines, Université de Bordeaux, Bordeaux, France.
  • Strube C; Institut universitaire de cardiologie et de pneumologie de Québec, Québec, Canada.
  • Mondoly P; Institut universitaire de cardiologie et de pneumologie de Québec, Québec, Canada.
  • Réant P; Hôpital Rangueil, University of Toulouse, Toulouse, France.
  • Sarrazin JF; Hôpital Haut-Lévêque, Bordeaux University, Bordeaux, France.
  • Galinier M; Institut universitaire de cardiologie et de pneumologie de Québec, Québec, Canada.
  • Champagne J; Hôpital Rangueil, University of Toulouse, Toulouse, France.
  • Rollin A; Institut universitaire de cardiologie et de pneumologie de Québec, Québec, Canada.
  • Carrié D; Hôpital Rangueil, University of Toulouse, Toulouse, France.
  • Cochet H; Hôpital Rangueil, University of Toulouse, Toulouse, France.
  • Lairez O; Hôpital Haut-Lévêque, Bordeaux University, Bordeaux, France.
  • Philippon F; Hôpital Rangueil, University of Toulouse, Toulouse, France.
  • Ferrières J; Institut universitaire de cardiologie et de pneumologie de Québec, Québec, Canada.
  • Maury P; Hôpital Rangueil, University of Toulouse, Toulouse, France.
  • Steinberg C; Hôpital Rangueil, University of Toulouse, Toulouse, France.
ESC Heart Fail ; 2024 Jul 23.
Article en En | MEDLINE | ID: mdl-39041575
ABSTRACT

AIM:

The diagnosis of hypertrophic cardiomyopathy (HCM) with moderate hypertrophy is challenging. Hypertensive heart disease (HHD) is the most common differential diagnosis that mimics the LVH of HCM. The aim of this study was to compare the QRS duration in HCM and HHD to create a novel diagnostic tool to identify primary HCM. METHODS AND

RESULTS:

We conducted an international retrospective multicentre study enrolling patients with true HCM and HHD. A total of 547 individuals with HCM and 139 with HHD were included. The median QRS duration was significantly shorter in HCM than in HHD (88 ms [80-94] vs. 98 ms [88-108]; P < 0.01). Multivariable logistic regression identified for the novel diagnostic HCM (D-HCM) score absence of antihypertensive drugs (+2); family history of unexplained sudden death (+2); QRS duration [<95 ms] = +1; maximum wall thickness (mm) [≥17] = +1. A cumulative QRS-HCM score ≥2 supports the diagnostic certainty of true HCM with a sensitivity of 79%, specificity of 99%, negative predictive value (NPV) of 55%, and positive predictive value (PPV) of 99%.

CONCLUSION:

The QRS duration in patient with HCM is significantly shorter compared with patients with HHD-related LVH. QRS duration can be used as a diagnosis marker to distinguish between HCM and HHD. The D-HCM score is a novel, simple, and accurate diagnosis tool for HCM patients with mild to moderate phenotypes.
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: ESC Heart Fail Año: 2024 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: ESC Heart Fail Año: 2024 Tipo del documento: Article